Lambert-Eaton myasthenic syndrome

Rituximab

Rituximab is a monoclonal antibody that binds to and depletes B lymphocytes. Small observational studies have demonstrated benefit in Lambert-Eaton myasthenic syndrome (LEMS), as well as in other immune-mediated neuromuscular diseases, including myasthenia gravis and inflammatory neuropathies.[49]Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):671-3. http://www.ncbi.nlm.nih.gov/pubmed/20392977?tool=bestpractice.com Although a randomised controlled study is underway for its use in myasthenia gravis, no trials are planned for use in LEMS.